*COMES IN LYOPHILIZED POWDER (FREEZE DRIED) MUST RECONSTITUTE*

R3TA (Research Compound)

R3TA is a cutting-edge synthetic peptide and investigational triple hormone receptor agonist designed for advanced metabolic research. It simultaneously targets the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors.

Molecular Profile R3TA is a 39-amino acid peptide derived from a GIP backbone, featuring strategic modifications including non-coded amino acids (such as Aib at positions 2 and 20, and α-methyl-leucine) and a C20 fatty diacid conjugation via a lysine side chain. These modifications enhance stability, half-life, and receptor binding affinity, making it suitable for in-depth laboratory investigations.

Mechanism of Action This multi-receptor approach allows R3TA to modulate key metabolic pathways in research models:

• Appetite regulation and satiety — through potent activation of GLP-1 and GIP pathways, which influence central and peripheral signaling related to food intake.
• Energy expenditure and fat metabolism — via glucagon receptor activation, which may promote lipolysis and thermogenesis in experimental settings.
• Glycemic control and insulin sensitivity — supporting studies on glucose homeostasis, nutrient metabolism, and related biochemical markers.

Researchers use R3TA to explore coordinated effects on energy balance, lipid profiles, and overall metabolic regulation in cellular and animal models.

Important Research Disclaimer: R3TA is sold strictly for research and laboratory use only. It is not for human consumption, therapeutic use, or any veterinary application. This product has not been approved by the FDA or any regulatory agency for human use. All handling, storage, and experimentation must comply with applicable laws, safety protocols, and institutional guidelines. Users assume full responsibility for proper research practices. Consult qualified professionals and review all safety data before use in any experimental setting.